Matthias Griese
Ludwig Maximilians Universität München · Klinikum der Universität München, Dr. von Haunersches Kinderspital · Pediatric Pneumology, Ludwig-Maximilians-University Munich
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthias Griese as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:30 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06431776 · Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).Savara Inc. · recruiting · Autoimmune Pulmonary Alveolar Proteinosis · principal investigator
- N/ANCT02852928 · European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and BiobankMatthias Griese · recruiting · Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia · study chair
- Ph2NCT02631603 · Stop Exogenous Allergic Alveolitis (EAA) in ChildhoodMatthias Griese · terminated · Hypersensitivity Pneumonitis, Exogenous Allergic Alveolitis · study director
- Ph2NCT02615938 · Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)Matthias Griese · terminated · Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease · principal investigator
- Ph2NCT00506688 · Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis PatientsMukoviszidose Institut gGmbH · completed · Cystic Fibrosis · principal investigator
- Ph2NCT00486837 · Deposition of Inhaled Prolastin in Cystic Fibrosis PatientsGrifols Therapeutics LLC · completed · Cystic Fibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:30 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.N Engl J Med · 20111,794 citationsRCR 48.8
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).Lancet Respir Med · 2014176 citationsRCR 6.3
- alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.Eur Respir J · 2007168 citationsRCR 4.4
- Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.Am J Respir Crit Care Med · 2021148 citationsRCR 11.1
- Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.Am J Respir Crit Care Med · 2018144 citationsRCR 6.5
- Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis.Am J Respir Crit Care Med · 2004136 citationsRCR 3.5
- 119 citationsRCR 3.5
- 95 citationsRCR 11.6
- 91 citationsRCR 4.5
- Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis.Am J Respir Crit Care Med · 200487 citationsRCR 2.4